Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiprelestat - Proteo Biotech

Drug Profile

Tiprelestat - Proteo Biotech

Alternative Names: Elafin

Latest Information Update: 23 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteo Biotech
  • Developer Proteo Biotech; Rhein Minapharm Biogenetics; Stanford University
  • Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Recombinant proteins
  • Mechanism of Action Leucocyte elastase inhibitors; Myeloblastin inhibitors; Pancreatic elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Pulmonary hypertension; Oesophageal cancer; Postoperative inflammation
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial reperfusion injury; Postoperative inflammation
  • Preclinical Lung disorders; Lung transplant rejection; Pulmonary arterial hypertension

Most Recent Events

  • 17 Jul 2018 Pharmacodynamics data from a preclinical study released by Proteo Biotech
  • 24 Jan 2018 Tiprelestat is still in preclinical trials for lung disorders in USA
  • 23 Jan 2018 Tiprelestat is still in phase II trials for postoperative inflammation associated with oesophagectomy for oesophageal carcinoma in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top